Nautilus Biotechnology (NAUT)
Builds the Voyager platform for intact-protein and proteoform analysis.
Something off on this page? Send us feedback.
Develops the Voyager platform, which uses Iterative Mapping to analyze intact proteins and proteoforms. The company is progressing from early access for a Tau proteoforms assay toward planned sales of instruments, reagents and proteome-analysis workflows.
Develops the Voyager platform to analyze intact proteins and proteoforms through Iterative Mapping, its proprietary analysis method. The company began external access with an Early Access Program for a Tau proteoforms assay and intends the offering to expand to Voyager instruments, reagents, targeted workflows and broadscale workflows for proteome analysis.
Based in Seattle and organized as a single reportable segment, Nautilus is a founder-led, development-stage life-sciences company. Its path from early access to commercial sales depends on platform validation, commercialization and customer adoption. Management's current plan calls for pre-orders to open before Voyager instrument shipments.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Dec 5, 2024 | Goldman Sachs | Downgrade | Neutral | Sell |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $84.0M · Total debt $27.8M · Total assets $163.6M · Shareholders' equity $131.1M
- Revenue
- $190.0K
- Operating income
- −$15.8M
- Net income
- −$14.5M
No dividends on record.
| Institutions81 holders · as of Mar 31, 2026 | 42.70% | 54.34M shares | |
| Insiders5 holders · as of Mar 4, 2026 | 34.55% | 43.97M shares | |
| Strategic holders1 holder · as of Feb 10, 2022 | 5.64% | 7.17M shares | |
| Otherremainder | 17.11% | 21.77M shares |
127.26M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Parag MallickInsiderdirector, 10 percent owner, officer: Chief Scientist | 17.73% | 22.56M | 13Dfiled Mar 4, 2026 ↗ |
Sujal M. Patel1Insiderdirector, 10 percent owner, officer: CEO, President, and Secretary | 16.70% | 21.25M | 13Dfiled Mar 4, 2026 ↗ |
Ah Capital Management, L.L.C.Institution | 13.87% | 17.65M | 13Fas of Mar 31, 2026 |
Perceptive Advisors LLCInstitution | 9.90% | 12.59M | 13Fas of Mar 31, 2026 |
Cercano Management LLCInstitution | 5.64% | 7.17M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Sujal M. Patel's transaction reports restate only vehicles that traded; the 2026 ownership statement (21.25M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. | 10 percent owner | −5,000,000 | $2.35 |
| Mar 4, 2026 | Sujal M. Patel | director, 10 percent owner, officer: CEO, President, and Secretary | +25,000 | $2.61 |
| Nov 6, 2025 | Kentaro Suzuki | officer: Chief Marketing Officer | +4,000 | $1.49 |
| Sep 5, 2025 | Sujal M. Patel | director, 10 percent owner, officer: CEO, President, and Secretary | +116,500 | $0.6742 |
| Sep 8, 2025 | Sujal M. Patel | director, 10 percent owner, officer: CEO, President, and Secretary | +83,500 | $0.6830 |
- Thermo Fisher Scientific
Orbitrap mass spectrometry and Olink proteomics at research scale
- Bruker
Mass spectrometry for deep proteomics and proteoform characterization
- Agilent Technologies
Mass spectrometry and chromatography for life-science workflows
- Seer
Deep, unbiased mass-spectrometry proteomics at scale
- Quantum-Si
Single-molecule protein sequencing for research proteomics
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nautilus Biotechnology | $0.9212 | −4.22% | $122.4M | — | — | 644.2 | — |
| Thermo Fisher Scientific | $608.54 | +0.02% | $226.15B | 32.7 | 23.2 | 4.9 | +10.5% |
| Bruker | $59.82 | +1.30% | $8.98B | — | 26.1 | 2.6 | +5.2% |
| Agilent Technologies | $152.51 | +0.75% | $42.76B | 29.8 | 23.0 | 5.8 | +8.1% |
| Seer | $1.93 | −2.53% | $108.9M | — | — | 7.9 | −23.4% |
| Quantum-Si | $0.7775 | +1.33% | $150.5M | — | — | 93.8 | −41.8% |
| Median | 31.3 | 23.2 | 5.8 | +5.2% |